Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon
<h2>Background</h2> <p>Cardiovascular diseases are the leading cause of death in Lebanon and Qatar. When lifestyle modifications prove insufficient, medication becomes a cornerstone in controlling such diseases and saving lives. Price, availability, and affordability hinder the equ...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | , |
| منشور في: |
2022
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513566605836288 |
|---|---|
| author | N. Abdel Rida (14153184) |
| author2 | M. I. Mohamed Ibrahim (14153187) Z. U. D. Babar (14153190) |
| author2_role | author author |
| author_facet | N. Abdel Rida (14153184) M. I. Mohamed Ibrahim (14153187) Z. U. D. Babar (14153190) |
| author_role | author |
| dc.creator.none.fl_str_mv | N. Abdel Rida (14153184) M. I. Mohamed Ibrahim (14153187) Z. U. D. Babar (14153190) |
| dc.date.none.fl_str_mv | 2022-11-22T21:17:56Z |
| dc.identifier.none.fl_str_mv | 10.1186/s12913-019-4828-0 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Relationship_between_pharmaceutical_pricing_strategies_with_price_availability_and_affordability_of_cardiovascular_disease_medicines_surveys_in_Qatar_and_Lebanon/21598386 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Health sciences Public health Cardiovascular disease Medicine access Medicine policy Generic medicine Medicines prices |
| dc.title.none.fl_str_mv | Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <h2>Background</h2> <p>Cardiovascular diseases are the leading cause of death in Lebanon and Qatar. When lifestyle modifications prove insufficient, medication becomes a cornerstone in controlling such diseases and saving lives. Price, availability, and affordability hinder the equitable access to medicines. The study aimed to assess prices, availability, and affordability of essential cardiovascular disease medicines in relation to pricing strategies in Qatar and Lebanon.</p> <h2>Methods</h2> <p>A cross-sectional survey using a variant of the World Health Organization and Health Action International (WHO/HAI) methodology as outlined in “Measuring medicine prices, availability, affordability and price components” (2008), second edition, was adopted. Prices and availability of 27 cardiovascular medicines were collected from public and private dispensing outlets. For international comparison, prices were adjusted to purchasing power parity. Data was analyzed across multiple sectors, within and across countries.</p> <h2>Results</h2> <p>A total of 15 public and private outlets were surveyed in each country. Prices were more uniform in Qatar than in Lebanon. In the public sector, medicines were free-of-charge in Lebanon and priced lower than the international reference prices in Qatar. The ratio of medicine unit price to international reference price in the private sectors surveyed are significantly higher than the acceptable threshold of 4. This ratio of originator brands and lowest priced generics in Qatar were up to two and five times those in Lebanon, respectively, even after adjusting for purchasing power parity. However, prices of lowest priced generics in the private sector were at least 35% cheaper in Qatar and 65% cheaper in Lebanon than their comparative originator brands. Medicines were more available in the private sector in Lebanon than in Qatar, but only the originator brand availability in the public sector in Qatar exceeded the WHO target of more than 80%. While affordable in the public sector in Qatar, four out of thirteen medicines exceeded the threshold in all private sectors covered. Hence, only the public sector in Qatar had a satisfying level of availability and affordability.</p> <h2>Conclusions</h2> <p>Except for the Qatari public sector, medicine prices, availability, and affordability are falling short from targets. Key policy decisions should be implemented to improve access to medicines.</p><h2>Other Information</h2> <p> Published in: BMC Health Services Research<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1186/s12913-019-4828-0" target="_blank">http://dx.doi.org/10.1186/s12913-019-4828-0</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_d87d4a73d1f865583e1164b8e124578c |
| identifier_str_mv | 10.1186/s12913-019-4828-0 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/21598386 |
| publishDate | 2022 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and LebanonN. Abdel Rida (14153184)M. I. Mohamed Ibrahim (14153187)Z. U. D. Babar (14153190)Biomedical and clinical sciencesCardiovascular medicine and haematologyHealth sciencesPublic healthCardiovascular diseaseMedicine accessMedicine policyGeneric medicineMedicines prices<h2>Background</h2> <p>Cardiovascular diseases are the leading cause of death in Lebanon and Qatar. When lifestyle modifications prove insufficient, medication becomes a cornerstone in controlling such diseases and saving lives. Price, availability, and affordability hinder the equitable access to medicines. The study aimed to assess prices, availability, and affordability of essential cardiovascular disease medicines in relation to pricing strategies in Qatar and Lebanon.</p> <h2>Methods</h2> <p>A cross-sectional survey using a variant of the World Health Organization and Health Action International (WHO/HAI) methodology as outlined in “Measuring medicine prices, availability, affordability and price components” (2008), second edition, was adopted. Prices and availability of 27 cardiovascular medicines were collected from public and private dispensing outlets. For international comparison, prices were adjusted to purchasing power parity. Data was analyzed across multiple sectors, within and across countries.</p> <h2>Results</h2> <p>A total of 15 public and private outlets were surveyed in each country. Prices were more uniform in Qatar than in Lebanon. In the public sector, medicines were free-of-charge in Lebanon and priced lower than the international reference prices in Qatar. The ratio of medicine unit price to international reference price in the private sectors surveyed are significantly higher than the acceptable threshold of 4. This ratio of originator brands and lowest priced generics in Qatar were up to two and five times those in Lebanon, respectively, even after adjusting for purchasing power parity. However, prices of lowest priced generics in the private sector were at least 35% cheaper in Qatar and 65% cheaper in Lebanon than their comparative originator brands. Medicines were more available in the private sector in Lebanon than in Qatar, but only the originator brand availability in the public sector in Qatar exceeded the WHO target of more than 80%. While affordable in the public sector in Qatar, four out of thirteen medicines exceeded the threshold in all private sectors covered. Hence, only the public sector in Qatar had a satisfying level of availability and affordability.</p> <h2>Conclusions</h2> <p>Except for the Qatari public sector, medicine prices, availability, and affordability are falling short from targets. Key policy decisions should be implemented to improve access to medicines.</p><h2>Other Information</h2> <p> Published in: BMC Health Services Research<br> License: <a href="http://creativecommons.org/licenses/by/4.0/" target="_blank">http://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="http://dx.doi.org/10.1186/s12913-019-4828-0" target="_blank">http://dx.doi.org/10.1186/s12913-019-4828-0</a></p>2022-11-22T21:17:56ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1186/s12913-019-4828-0https://figshare.com/articles/journal_contribution/Relationship_between_pharmaceutical_pricing_strategies_with_price_availability_and_affordability_of_cardiovascular_disease_medicines_surveys_in_Qatar_and_Lebanon/21598386CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/215983862022-11-22T21:17:56Z |
| spellingShingle | Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon N. Abdel Rida (14153184) Biomedical and clinical sciences Cardiovascular medicine and haematology Health sciences Public health Cardiovascular disease Medicine access Medicine policy Generic medicine Medicines prices |
| status_str | publishedVersion |
| title | Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon |
| title_full | Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon |
| title_fullStr | Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon |
| title_full_unstemmed | Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon |
| title_short | Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon |
| title_sort | Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Health sciences Public health Cardiovascular disease Medicine access Medicine policy Generic medicine Medicines prices |